Efficacy of Lenvatinib Plus Pembrolizumab and Sunitinib in Advanced RCC
Viktor Grünwald, MD, PhD, reviews the efficacy findings of lenvatinib combined with pembrolizumab and sunitinib for the treatment of patients with advanced renal cell carcinoma.
Viktor Grünwald, MD, PhD, of Hannover Medical School, reviews the efficacy findings of lenvatinib (Lenvima) combined with pembrolizumab (Keytruda) and sunitinib (Sutent) for the treatment of patients with advanced renal cell carcinoma (RCC) presented during the 2021 American Society of Clinical Oncology Annual Meeting.
In the CLEAR study, investigators noticed an impact in efficacy that was irrespective of the adverse event profile. In terms of progression-free survival, the results were similar in patients who were considered to have favorable risk and those who had at least 1 risk parameter. Grunwald also states that the highest complete responders to the combination were those with favorable risk.
The findings related to the difference between patients with favorable-risk and high-risk advanced RCC are descriptive, notes Grunwald and require further research.
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Deciding Factors for Front-Line Therapy in Metastatic RCC
April 17th 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic renal cell carcinoma in the first article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
